Beacon Healthcare (2170.HK): Revenue and gross profit both increased by 50%, major acquisitions helped build the Chinese version of Vitrolife

Since Beijing first included 16 assisted reproduction programs in health insurance in June of last year, under the impetus of the National Health Insurance Administration, Guangxi, Inner Mongolia, Gansu and other places have followed suit and included some assisted reproduction programs in medical insurance, including egg retrieval, embryo culture, embryo transfer, sperm selection, diagnosis of embryonic genetic diseases (PGT-M), pre-implantation embryonic genetic testing (PGT-SR) for chromosomal diseases, and cell freezing. The overall reimbursement rate for these projects is as high as 50%-70%, and some projects can even be reimbursed twice.

Gelonghui FinanceApr 3 09:45 ET

BASECARE MEDICAL-B (02170. HK) Announces Annual Performance: Revenue and Gross Profit Growth of 48% and 53%, Completing Acquisition of BMX to Accelerate Globalization Layout

Basecare Medical-B (02170. HK) announced its annual performance. As of December 31, 2023, the group's revenue was RMB 208 million, a year-on-year increase of approximately 48%; The gross profit was RM

Gelonghui FinanceMar 29 02:42 ET

Beckon Medical-B (02170.HK) announced annual results: gross profit increased 48% and 53% year over year, completed the acquisition of Singapore BMX to accelerate global layout

Gelonghui, March 29丨Beacon Medical-B (02170.HK) announced its annual results. For the year ended December 31, 2023, the Group's revenue was RMB 208 million, up about 48% year on year; gross profit was RMB 91.351 million, up about 53% year on year; the Group's overall gross margin was 43.9%, which is basically the same as 42.2% for the year ended December 31, 2022. The increase in revenue was mainly due to (i) the steady increase in sales of PGT kits, (ii) the increase in sales of ultra-low temperature storage equipment and smart liquid nitrogen tanks; and (iii) embryo incubators and

Gelonghui FinanceMar 29 01:11 ET

Beckon Medical-B (02170) announces 2023 results, shareholders' equity losses of about 192 million yuan, an increase of 56.27% year-on-year

According to the Zhitong Finance App, Beacon Medical-B (02170) announced its 2023 results, with revenue of about 208 million yuan, up 47.6% year on year; loss attributable to the company's equity shareholders was about 192 million yuan, an increase of 56.27% year on year; loss per share was 0.7 yuan. According to the announcement, the increase in revenue was mainly due to the steady increase in sales of PGT kits, the increase in sales of ultra-low temperature storage equipment and smart liquid nitrogen tanks; and the increase in revenue from sales of consumables such as embryo incubators and culture medium.

Zhitong FinanceMar 28 08:39 ET

BASECARE-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Futu NewsMar 28 07:54 ET · Announcements

Beacon Medical-B (02170.HK) will hold a board meeting on March 28 to approve the full year results

Gelonghui, March 18 | Beckon Medical-B (02170.HK) announced that the company will hold a board meeting on March 28, 2024 to adopt the annual results of the company and its subsidiaries for the year ended 31 December 2023 and consider the payment of a final dividend (if any).

Gelonghui FinanceMar 18 04:51 ET